Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.

William J Sandborn,Geert R D'Haens,Bruce E Sands,Remo Panaccione,Siew C Ng,Nervin Lawendy,Nicole Kulisek,Irene Modesto,Xiang Guo,Rajiv Mundayat,Chinyu Su,Ivana Vranic,Julian Panés

Journal of Crohn's & colitis（2023）

引用 20|浏览36

暂无评分

摘要

AESI IRs were stable to 7.8 years and generally <2.0 in the Overall plus P3b/4 [2020] Cohort, with the exception of herpes zoster [a known risk of tofacitinib treatment]. ClinicalTrials.gov:NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304JCC Topic/keyword selection: 3. Clinical trials.

查看译文

关键词

Ulcerative colitis,safety,tofacitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要